Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of bortezomib in treating patients who have
persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer. Bortezomib
may stop the growth of cancer cells by blocking the enzymes necessary for their growth.